Drug General Information (ID: DDI9R846VF)
Drug Name			Nabumetone		Drug Info		Rofecoxib		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Nsaids/Analgesics				Antiinflammatory Agents
Structure

Mechanism of Nabumetone-Rofecoxib Interaction (Severity Level: Moderate)
Increased risk of GI mucosal injury/bleeding risk Click to Show/Hide Mechanism Graph
Drug Name		Nabumetone				Rofecoxib
Mechanism		GI mucosal injury/bleeding risk				GI mucosal injury/bleeding risk
Key Mechanism Factor 1
		Factor Name		Gastrointestinal toxicity
		Factor Description		The risk and severity of gastrointestinal toxicity, including inflammation, bleeding, ulceration, and perforation, increases when drugs with gastrointestinal mucosal irritant effects are combined.
Mechanism Description		Increased risk of GI mucosal injury/bleeding risk by the combination of Nabumetone and Rofecoxib

Recommended Action
Management		The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Cerner Multum, Inc "ANVISA Bulario Eletrnico." .